2. Search Result
Search Result
Results for "

inhibits HIV-1 entry

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

11

Peptides

1

Inhibitory Antibodies

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N4100
    Trilobatin
    5+ Cited Publications

    		 TNF Receptor HIV SGLT Infection
    Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd , Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects . Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
    Trilobatin
  • HY-P1066
    Apelin-17(human, bovine)

    		Apelin Receptor (APJ) HIV Infection
    Apelin-17(human, bovine) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-17(human, bovine)
  • HY-115488A
    BNM-III-170

    		HIV Infection
    BNM-III-170, CD4-mimeticcompound, is an anti-HIV-1 agent. BNM-III-170 binds to the Phe43 cavity of HIV 1 gp120. BNM-III-170 can inhibits HIV-1 viral entry into target cells. BNM-III-170 can be used for the research of HIV-1 infection .
    BNM-III-170
  • HY-P1064
    Apelin-36(human)

    		Apelin Receptor (APJ) HIV Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-36(human)
  • HY-P991246
    VRC01LS

    		Virus Protease HIV Infection
    VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
    VRC01LS
  • HY-107401
    Ancriviroc

    SCH-351125

    		 HIV CCR Calcium Channel Infection
    Ancriviroc (SCH-351125) is an orally active CCR5 antagonist with an IC50 value of 13 nM against hCCR5. Ancriviroc specifically binds to hCCR5, blocks ligand-induced signal transduction, calcium influx, GTPγS binding, chemotaxis, ligand binding, and HIV-1 entry, induces conformational changes in CCR5, and inhibits infection and replication of R5-tropic HIV-1 .
    Ancriviroc
  • HY-76648
    NBD-556

    		HIV Infection
    NBD-556, a CD4 mimetic, is a potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 shows potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels .
    NBD-556
  • HY-P1065
    Apelin-36(rat, mouse)

    		Apelin Receptor (APJ) HIV Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(rat, mouse) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ .
    Apelin-36(rat, mouse)
  • HY-125183
    BMS-818251

    		HIV Infection
    BMS-818251 is a HIV-1 attachment and entry inhibitor. BMS-818251 binds to HIV-1 Env gp120, interferes with viral attachment and entry processes, and inhibits HIV-1 viral replication. BMS-818251 can be used in studies related to HIV-1 infection .
    BMS-818251
  • HY-P1064A
    Apelin-36(human) TFA

    		HIV Apelin Receptor (APJ) Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC550=8.61). Apelin-36(human) TFA has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-36(human) TFA
  • HY-N3222
    Myriceric acid B

    		HIV Infection Cancer
    Myriceric acid B is a potent HIV-1 entry inhibitor targeting gp41. Myriceric acid B is an antitumor agent .
    Myriceric acid B
  • HY-163362
    HIV-1 inhibitor-65

    		Reverse Transcriptase PKC HIV Infection
    HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC50: 2.9 nM) and an activator of protein kinase C (PKC). HIV-1 inhibitor-65 inhibits syncytium formation (EC50: 7.0 nM) and inhibits HIV-1 entry and HIV-1 reverse transcriptase .
    HIV-1 inhibitor-65
  • HY-N4100R
    Trilobatin (Standard)

    		TNF Receptor Reference Standards HIV SGLT Infection
    Trilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd , Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope . Neuroprotective effects . Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells .
    Trilobatin (Standard)
  • HY-123902
    Ophiobolin C

    Zizanin A

    		 CCR HIV Infection
    Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells . Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells .
    Ophiobolin C
  • HY-P4810
    Polyphemusin II-Derived Peptide

    T140

    		 CXCR Infection
    Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .
    Polyphemusin II-Derived Peptide
  • HY-P1066A
    Apelin-17(human, bovine) TFA

    		HIV Apelin Receptor (APJ) Infection
    Apelin-17(human, bovine) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) TFA binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ .
    Apelin-17(human, bovine) TFA
  • HY-123884
    GSK-214096

    		CCR HIV Infection
    GSK-214096 is a selective CCR5 antagonist and an inhibitor of HIV-1 entry. GSK-214096 inhibits HIV-1 glycoprotein 120 (gp120) .
    GSK-214096
  • HY-172603
    HIV-1-IN-82

    		HIV Infection
    HIV-1-IN-82 (Compound L14) is an orally active small-molecule entry inhibitor for HIV-1 with an IC50 value of 0.39 μM. HIV-1 inhibitor-82 is promising for research of anti-HIV-1 infection .
    HIV-1-IN-82
  • HY-P10437
    VIRIP

    human α1-AT(353-372)

    		 HIV Infection
    VIRIP (human α1-AT(353-372)) is a HIV-1 inhibitor. VIRIP blocks the entry of HIV-1 by interacting with gp41 fusion peptide. VIRIP can be used for virus research .
    VIRIP
  • HY-116113
    SJP-L-5

    		HIV DNA/RNA Synthesis Infection
    SJP-L-5 is an HIV-1 capsid dissociation inhibitor. SJP-L-5 exhibits inhibitory activity against multiple HIV-1 strains, with an EC50 ranging from 0.16 to 0.97 μg/mL. SJP-L-5 inhibits viral infection by blocking HIV-1 viral DNA entry into the nucleus. SJP-L-5 can be used in HIV-1 infection research .
    SJP-L-5
  • HY-P11037
    soVIRIP

    		HIV Infection
    soVIRIP is a virus inhibitory peptide with an IC50 of 1.2  μM for HIV-1 . soVIRIP binds to the HIV-1 GP41 fusion peptide and inhibits viral fusion and entry into host cells. soVIRIP has broad-spectrum anti-HIV-1 activities with nontoxicity in zebrafish models. soVIRIP can used for viral infections research .
    soVIRIP
  • HY-123768
    SCH 350581

    AD-101

    		 CCR Infection
    SCH 350581 (AD-101) is a CCR5 antagonist. SCH 350581 inhibits HIV-1 replication, viral entry into cells, and the binding of gp120 to cell lines in primary lymphocytes .
    SCH 350581
  • HY-106971
    PD 161374

    		HIV Infection
    PD 161374 is an inhibitor targeting the HIV-1 nucleocapsid protein NCp7. PD 161374 primarily acts on the early stages of viral replication, inhibiting the completion of reverse transcription without affecting viral entry or later assembly. PD 161374 remains active against HIV-1, HIV-2, SIV, and drug-resistant strains. PD 161374 can be used to study antiretroviral agents .
    PD 161374
  • HY-P10801
    mC46 peptide

    C46 peptide

    		 HIV Infection
    mC46 (C46) peptide is a membrane-associated fusion peptide inhibitor. mC46 peptide potently inhibits HIV-1 replication and entry. mC46 also inhibits CCR5-tropic, CXCR4-tropic, and dual-tropic HIVs, SIV, and SHIV .
    mC46 peptide
  • HY-P10429
    RCP168

    		CXCR Infection
    RCP168 is a highly selective and affinity CXCR4 receptor antagonist (IC50=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via CXCR4 receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between CXCR4 receptor and other chemical factor receptors .
    RCP168
  • HY-146338
    RPR103611

    		HIV Infection
    RPR103611, the betulinic acid derivative, is a potent HIV-1 entry inhibitor with IC50s of 80, 0.27, and 0.17 for CCR5-tropic virus YU2, CXCR4-tropic virus NL4-3 and dual tropic virus 89.6, respectively .
    RPR103611
  • HY-134809A
    Cyclotriazadisulfonamide hydrochloride

    CADA hydrochloride

    		 HIV Infection
    Cyclotriazadisulfonamide (CADA) hydrochloride is a specific CD4-targeted HIV entry inhibitor with activity against HIV-1 replication. Cyclotriazadisulfonamide hydrochloride can specifically downregulate the expression of CD4 receptors on the cell surface, effectively inhibiting HIV transmission. Cyclotriazadisulfonamide hydrochloride can inhibit HIV-1(NL4.3) and SIV(mac251), and has a synergistic effect when used in combination with cellulose acetate (CAP). Cyclotriazadisulfonamide hydrochloride can also be used as a microbial gel formulation to maintain CD4 downregulation and antiviral activity, and is a broad-spectrum anti-HIV agent.
    Cyclotriazadisulfonamide hydrochloride
  • HY-P1065A
    Apelin-36(rat, mouse) TFA

    		HIV Apelin Receptor (APJ) Infection Cardiovascular Disease Metabolic Disease
    Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) TFA blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ .
    Apelin-36(rat, mouse) TFA
  • HY-167945
    AMD-3329

    		HIV CXCR Infection
    AMD-3329 is a potent and selective anti-HIV-1 and HIV-2 agent, exhibiting activity by inhibiting virus replication through binding to the chemokine receptor CXCR4, which serves as a co-receptor for the entry of X4 viruses.
    AMD-3329
  • HY-182376
    JRC-I-191

    		HIV Infection
    JRC-I-191 is an anti-HIV-1 agent. JRC-I-191 inhibits HIV-1 YU-2 entry into cells. JRC-I-191 does not inhibit infection of cells by amphotropic murine leukemia virus. JRC-I-191 can be used for the research of HIV-1 infection .
    JRC-I-191
  • HY-115488
    BNM-III-170 free base

    		HIV Infection
    BNM-III-170 free base, CD4-mimeticcompound, is an anti-HIV-1 agent. BNM-III-170 free base, binds to the Phe43 cavity of HIV 1 gp120. BNM-III-170 can inhibits HIV-1 viral entry into target cells. BNM-III-170 free base, can be used for the research of HIV-1 infection .
    BNM-III-170 free base
  • HY-182514
    BMMP

    		HIV hnRNP Infection Cancer
    BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer .
    BMMP
  • HY-180563
    ADC 38 drug linker

    		Drug-Linker Conjugates for ADC Infection
    ADC 38 drug linker is a drug linker coupling agent used for ADCs, consisting of a CD4 mimic and a linker. ADC 38 drug linker can be used to synthesize antibody-drug conjugates (ADCs), such as ADC 38 .
    ADC 38 drug linker

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: